PT951282E - Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2 - Google Patents
Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2 Download PDFInfo
- Publication number
- PT951282E PT951282E PT97911412T PT97911412T PT951282E PT 951282 E PT951282 E PT 951282E PT 97911412 T PT97911412 T PT 97911412T PT 97911412 T PT97911412 T PT 97911412T PT 951282 E PT951282 E PT 951282E
- Authority
- PT
- Portugal
- Prior art keywords
- agonists
- prevention
- treatment
- receptor subtype
- subtype selective
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title abstract 2
- 229960002986 dinoprostone Drugs 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3356996P | 1996-12-20 | 1996-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT951282E true PT951282E (pt) | 2008-06-09 |
Family
ID=21871174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97911412T PT951282E (pt) | 1996-12-20 | 1997-11-27 | Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6426359B1 (pt) |
| EP (1) | EP0951282B1 (pt) |
| JP (2) | JP2000507961A (pt) |
| KR (1) | KR100359557B1 (pt) |
| AT (1) | ATE390917T1 (pt) |
| AU (1) | AU4881697A (pt) |
| CA (1) | CA2275595C (pt) |
| CY (1) | CY2610B2 (pt) |
| DE (1) | DE69738613T2 (pt) |
| DK (1) | DK0951282T3 (pt) |
| ES (1) | ES2303341T3 (pt) |
| HU (1) | HUP0001836A3 (pt) |
| IL (2) | IL130333A0 (pt) |
| MY (1) | MY132818A (pt) |
| NZ (1) | NZ335770A (pt) |
| PT (1) | PT951282E (pt) |
| TW (1) | TW562677B (pt) |
| WO (1) | WO1998027976A1 (pt) |
| ZA (1) | ZA9711435B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| JP2000507961A (ja) | 1996-12-20 | 2000-06-27 | ファイザー・インク | Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療 |
| EP1000619A3 (en) * | 1998-06-23 | 2002-07-24 | Pfizer Products Inc. | Method for treating glaucoma |
| US6414006B1 (en) | 1998-10-15 | 2002-07-02 | Merck Frosst Canada & Co. | Methods for inhibiting bone resorption |
| WO2000029614A1 (en) * | 1998-11-12 | 2000-05-25 | Gemini Genomics Ab. | Human prostaglandin receptors and methods of use thereof |
| NZ513825A (en) | 1999-03-05 | 2001-09-28 | Procter & Gamble | C 16 unsaturated FP-selective prostaglandins analogs |
| TWI247606B (en) * | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| WO2001046140A1 (en) * | 1999-12-22 | 2001-06-28 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
| US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| FR2812192B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| FR2812190B1 (fr) * | 2000-07-28 | 2003-01-31 | Oreal | Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils |
| EP1448182A1 (en) * | 2001-11-30 | 2004-08-25 | Pfizer Products Inc. | Pharmaceutical compositions and methods for administering ep 2 receptor selective agonists |
| WO2004073591A2 (en) * | 2003-02-24 | 2004-09-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2) |
| JP2006519250A (ja) * | 2003-03-04 | 2006-08-24 | ファイザー・プロダクツ・インク | 医療処置におけるｅｐ２選択的受容体アゴニストの使用 |
| EP1661580B1 (en) * | 2003-07-25 | 2014-01-08 | Ono Pharmaceutical Co., Ltd. | Remedy for cartilage-related diseases |
| WO2005027931A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist |
| WO2005080367A1 (en) | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| DK1846354T3 (da) | 2005-01-14 | 2010-08-16 | Allergan Inc | Substituterede cyclopentaner eller cyclopentanoner til behandling af okular hypertensive tilstande |
| JP2009505973A (ja) | 2005-08-09 | 2009-02-12 | アステランド ユーケイ リミテッド | Ｅｐ２受容体アゴニスト |
| US7323591B2 (en) | 2006-01-10 | 2008-01-29 | Allergan, Inc. | Substituted cyclopentanes or cyclopentanones as therapeutic agents |
| US8063240B2 (en) * | 2007-11-14 | 2011-11-22 | Cayman Chemical Company, Incorporated | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions |
| WO2009140205A2 (en) | 2008-05-15 | 2009-11-19 | Allergan, Inc. | Therapeutic substituted cyclopentanes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4033996A (en) * | 1973-04-25 | 1977-07-05 | Merck & Co., Inc. | 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins |
| US4018892A (en) | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
| US4112236A (en) * | 1977-04-04 | 1978-09-05 | Merck & Co., Inc. | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins |
| AU615534B2 (en) | 1988-04-19 | 1991-10-03 | Teijin Limited | 2-substituted-2-cyclopentenones |
| US5409911A (en) | 1992-09-11 | 1995-04-25 | Merck & Co., Inc. | Prostaglandin analog for treating osteoporosis |
| US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| US5698598A (en) | 1995-08-04 | 1997-12-16 | Allergan | EP2 -receptor agonists as agents for lowering intraocular pressure |
| JP2000507961A (ja) | 1996-12-20 | 2000-06-27 | ファイザー・インク | Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療 |
| UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
-
1997
- 1997-11-27 JP JP10528575A patent/JP2000507961A/ja not_active Withdrawn
- 1997-11-27 EP EP97911412A patent/EP0951282B1/en not_active Expired - Lifetime
- 1997-11-27 NZ NZ335770A patent/NZ335770A/en not_active IP Right Cessation
- 1997-11-27 KR KR1019997005528A patent/KR100359557B1/ko not_active IP Right Cessation
- 1997-11-27 WO PCT/IB1997/001483 patent/WO1998027976A1/en active IP Right Grant
- 1997-11-27 AT AT97911412T patent/ATE390917T1/de active
- 1997-11-27 DK DK97911412T patent/DK0951282T3/da active
- 1997-11-27 CA CA002275595A patent/CA2275595C/en not_active Expired - Fee Related
- 1997-11-27 ES ES97911412T patent/ES2303341T3/es not_active Expired - Lifetime
- 1997-11-27 DE DE69738613T patent/DE69738613T2/de not_active Expired - Lifetime
- 1997-11-27 IL IL13033397A patent/IL130333A0/xx active IP Right Grant
- 1997-11-27 PT PT97911412T patent/PT951282E/pt unknown
- 1997-11-27 AU AU48816/97A patent/AU4881697A/en not_active Abandoned
- 1997-11-27 US US09/331,078 patent/US6426359B1/en not_active Expired - Fee Related
- 1997-11-27 HU HU0001836A patent/HUP0001836A3/hu unknown
- 1997-12-17 TW TW086119114A patent/TW562677B/zh active
- 1997-12-18 MY MYPI97006111A patent/MY132818A/en unknown
- 1997-12-19 ZA ZA9711435A patent/ZA9711435B/xx unknown
-
1999
- 1999-06-07 IL IL130333A patent/IL130333A/en not_active IP Right Cessation
-
2006
- 2006-05-22 JP JP2006141297A patent/JP2006290895A/ja active Pending
-
2008
- 2008-06-05 CY CY0800012A patent/CY2610B2/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006290895A (ja) | 2006-10-26 |
| ATE390917T1 (de) | 2008-04-15 |
| DE69738613T2 (de) | 2009-04-30 |
| HUP0001836A3 (en) | 2001-05-28 |
| KR20000057680A (ko) | 2000-09-25 |
| DK0951282T3 (da) | 2008-07-14 |
| CA2275595C (en) | 2003-08-05 |
| TW562677B (en) | 2003-11-21 |
| AU4881697A (en) | 1998-07-17 |
| ZA9711435B (en) | 1999-06-21 |
| IL130333A (en) | 2007-02-11 |
| CA2275595A1 (en) | 1998-07-02 |
| JP2000507961A (ja) | 2000-06-27 |
| US6426359B1 (en) | 2002-07-30 |
| KR100359557B1 (ko) | 2002-11-08 |
| MY132818A (en) | 2007-10-31 |
| ES2303341T3 (es) | 2008-08-01 |
| NZ335770A (en) | 2005-01-28 |
| IL130333A0 (en) | 2000-06-01 |
| CY2610B2 (en) | 2010-10-22 |
| HUP0001836A2 (hu) | 2000-09-28 |
| EP0951282A1 (en) | 1999-10-27 |
| EP0951282B1 (en) | 2008-04-02 |
| DE69738613D1 (de) | 2008-05-15 |
| WO1998027976A1 (en) | 1998-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2610B2 (en) | Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 a gonists | |
| BG102690A (en) | Il-8 receptor antagonists | |
| PL331091A1 (en) | Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor | |
| DE69626660D1 (en) | 2-alkylpyrrolidine | |
| GB2333453A (en) | Colostrinin and uses thereof | |
| YU18400A (sh) | Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja | |
| MX9704640A (es) | Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion. | |
| AU3508497A (en) | Androgen receptor modulator compounds and methods | |
| BG102999A (en) | New 2,3-diasubstituted-4-(3h)-quinazolinons | |
| NO964966L (no) | Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav | |
| WO2000006085A3 (en) | Compounds and methods | |
| AU1753699A (en) | Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear | |
| ID27820A (id) | APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF | |
| EP0909561A3 (en) | Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder | |
| IL110943A (en) | Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders | |
| BR9510499A (pt) | Antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados po il-5 | |
| EP1632248B8 (en) | Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness | |
| DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
| AU3745795A (en) | Use of CCK-B receptor antagonists for the treatment of sleepdisorders | |
| TR199900505T2 (pt) | ||
| HK1022267A1 (en) | Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis | |
| DE3378979D1 (en) | 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents | |
| EP1083914A4 (en) | TREATING ARTHRITIS AND OTHER SIMILAR DISORDERS | |
| DK0956038T3 (da) | Morfogen peptidinduceret regeneration af senseopfattelsesvæv | |
| PT1017377E (pt) | Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina |